50 Best Peptides

This website is for informational purposes only and does not constitute medical advice. Read disclaimer

#120

Daptomycin

AntimicrobialCubicinCubicin RFLY146032

A cyclic lipopeptide antibiotic approved for treating serious Gram-positive bacterial infections, including MRSA, with a unique calcium-dependent membrane depolarization mechanism.

Share:

Overview

Daptomycin is a cyclic lipopeptide antibiotic derived from Streptomyces roseosporus. Developed by Eli Lilly and later brought to market by Cubist Pharmaceuticals (now part of Merck), daptomycin was approved by the FDA in 2003 for complicated skin and soft tissue infections (cSSTI) and in 2006 for Staphylococcus aureus bacteremia and right-sided endocarditis, including cases caused by methicillin-resistant S. aureus (MRSA).

The mechanism of action is unique among antibiotics. Daptomycin inserts into bacterial cell membranes in a calcium-dependent manner. The peptide binds to the membrane and oligomerizes, forming ion-conducting channels that cause rapid depolarization of the membrane potential. This depolarization leads to cessation of DNA, RNA, and protein synthesis without direct cell lysis, resulting in bacterial death. The calcium-dependent nature of this mechanism distinguishes daptomycin from all other classes of antibiotics.

A critical clinical consideration is that daptomycin is inactivated by pulmonary surfactant. When the drug contacts surfactant in the lungs, it binds to the surfactant lipids and loses its antimicrobial activity. This is why daptomycin is specifically contraindicated for the treatment of pneumonia, despite being effective against the causative organisms in vitro. This limitation was identified during clinical trials where daptomycin failed to demonstrate non-inferiority to comparator antibiotics for community-acquired pneumonia.

Daptomycin has become a cornerstone of treatment for serious Gram-positive infections, particularly those caused by MRSA and vancomycin-resistant Enterococci (VRE). Its rapid bactericidal activity, once-daily dosing, and generally favorable safety profile have made it a preferred agent in many clinical scenarios. Monitoring of creatine phosphokinase (CPK) levels is recommended during therapy due to the risk of skeletal muscle toxicity.

Research Uses & Applications

  • FDA-approved treatment of complicated skin and soft tissue infections (cSSTI)
  • FDA-approved treatment of S. aureus bacteremia and right-sided endocarditis (including MRSA)
  • Off-label use for vancomycin-resistant Enterococcal (VRE) infections
  • Treatment of bone and joint infections caused by Gram-positive organisms
  • Alternative to vancomycin for MRSA infections, particularly in patients with renal impairment
  • Used in prosthetic device-related infections as part of combination therapy

Key Research Findings

  • Phase 3 trials demonstrated non-inferiority of daptomycin to standard therapy (vancomycin or anti-staphylococcal penicillins) for S. aureus bacteremia and endocarditis.
  • In vitro studies showed rapid concentration-dependent bactericidal activity, with greater than 99.9% killing within 1-2 hours at therapeutic concentrations.
  • Clinical data confirmed that daptomycin is inactivated by pulmonary surfactant, explaining its failure in pneumonia trials despite in vitro susceptibility.
  • Studies showed daptomycin retained activity against vancomycin-intermediate S. aureus (VISA) and heterogeneous VISA (hVISA) isolates in most cases.
  • Pharmacokinetic studies supported once-daily dosing at 4-6 mg/kg for standard indications, with higher doses (8-12 mg/kg) explored for deep-seated infections.

Risks & Side Effects

  • Skeletal muscle toxicity: elevated CPK levels and rare cases of rhabdomyolysis require monitoring.
  • Not effective for pneumonia due to inactivation by pulmonary surfactant.
  • Eosinophilic pneumonia is a rare but serious adverse effect that requires immediate discontinuation.
  • Potential for peripheral neuropathy with prolonged use.
  • Development of daptomycin resistance (non-susceptibility) has been reported during prolonged therapy, particularly in deep-seated infections.

Administration

Administered intravenously once daily. Dosing: 4 mg/kg for cSSTI, 6 mg/kg for S. aureus bacteremia and endocarditis. Higher doses (8-12 mg/kg) are sometimes used off-label for deep-seated or difficult-to-treat infections. Infused over 30 minutes or administered as a 2-minute IV push. CPK levels should be monitored weekly. Dose adjustment required in renal impairment (CrCl < 30 mL/min).

Legal Status

FDA-approved prescription antibiotic (2003 for cSSTI, 2006 for bacteremia/endocarditis). Marketed as Cubicin and Cubicin RF. Available by prescription only. Generic daptomycin available following patent expiration. Classified as a critically important antimicrobial by the WHO.

Frequently Asked Questions

What is Daptomycin?

A cyclic lipopeptide antibiotic approved for treating serious Gram-positive bacterial infections, including MRSA, with a unique calcium-dependent membrane depolarization mechanism.

What are the main uses of Daptomycin?

The primary research applications of Daptomycin include: FDA-approved treatment of complicated skin and soft tissue infections (cSSTI); FDA-approved treatment of S. aureus bacteremia and right-sided endocarditis (including MRSA); Off-label use for vancomycin-resistant Enterococcal (VRE) infections; Treatment of bone and joint infections caused by Gram-positive organisms; Alternative to vancomycin for MRSA infections, particularly in patients with renal impairment; Used in prosthetic device-related infections as part of combination therapy.

What are the risks and side effects of Daptomycin?

Documented risks and side effects include: Skeletal muscle toxicity: elevated CPK levels and rare cases of rhabdomyolysis require monitoring.; Not effective for pneumonia due to inactivation by pulmonary surfactant.; Eosinophilic pneumonia is a rare but serious adverse effect that requires immediate discontinuation.; Potential for peripheral neuropathy with prolonged use.; Development of daptomycin resistance (non-susceptibility) has been reported during prolonged therapy, particularly in deep-seated infections.. Always consult a healthcare professional before considering any peptide.

Is Daptomycin legal?

FDA-approved prescription antibiotic (2003 for cSSTI, 2006 for bacteremia/endocarditis). Marketed as Cubicin and Cubicin RF. Available by prescription only. Generic daptomycin available following patent expiration. Classified as a critically important antimicrobial by the WHO.

How is Daptomycin administered?

Administered intravenously once daily. Dosing: 4 mg/kg for cSSTI, 6 mg/kg for S. aureus bacteremia and endocarditis. Higher doses (8-12 mg/kg) are sometimes used off-label for deep-seated or difficult-to-treat infections. Infused over 30 minutes or administered as a 2-minute IV push. CPK levels should be monitored weekly. Dose adjustment required in renal impairment (CrCl < 30 mL/min).

Related Peptides

#116

Nisin

Antimicrobial

#117

Polymyxin B

Antimicrobial

#118

Bacitracin

Antimicrobial

#119

Gramicidin

Antimicrobial

Stay Updated on Peptide Research

Get the latest peptide research news and updates delivered to your inbox.

Official Store

Experience Peptides on Your Skin

Shop our curated collection of peptide-infused skincare — Copper Peptide serums, anti-aging treatments, hydrogel patches, and more.

Shop Peptide Skincare

Important Disclaimer

The information on this page is for educational and informational purposes only. It is not intended as medical advice. Always consult a qualified healthcare professional before considering any peptide or supplement. 50 Best Limited does not endorse, recommend, or promote the use of any peptide for self-administration. Read our full disclaimer.

← #119 Gramicidin#121 Vancomycin →